About MIXiii-BIOMED 2018
Dear Friends and Colleagues,
It is our honor and pleasure to invite you to participate in the 17th MIXiii-BIOMED 2018 Conference and Exhibition, to be held May 15-17, 2018 in Tel Aviv, Israel.
This year we will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life sciences. The conference will be divided into 9 tracks:
- Digital Health, IoT, and Big Data – New Armamentarium in Medicine
- Next Generation Oncology Treatments
- Brain Health
- Personalized Diagnostics and Treatments
- Fighting Rare Genetic Diseases Using Novel Therapeutic Approaches
- Nanomedicine and its Role in New Medical Therapeutics
- From Academia Research to Industry
- Cutting Edge Medical Device Technologies: Metabolic, Ophthalmology
- Novel Clinical Trial Designs and Technologies to Accelerate Drug Development
As we envision and analyze our projections for the future of healthcare systems, we should address ways to diagnose and treat patients by utilizing next generation methods. With the goal of improving the way we treat, prevent and cure diseases, we should consider innovations in precision and targeted medicine genetics, personal diagnosis, treatment and monitoring.
When & Where
Conference Halls, Exhibition Hall, Networking Area,
Satellite Events and Meeting Rooms
INVITED SPEAKERS (Preliminary List)
Arie S. Belldegrun, MD, FACS
Founder, Kite Pharma; Executive Chairman & Co-Founder, Allogene Therapeutics
Francois Maisonrouge
Senior Managing Director, Evercore Partners
Bruce R. Rosengard, MD
Vice President, External Innovation, Medical Devices, Johnson and Johnson Medical Devices
Paul R. Biondi
Senior Vice President, Head of Business Development, Bristol-Myers Squibb
Philip Nelson
Director of Engineering at Google Research
Anat Naschitz
Managing Director, Orbimed Advisors
Allen Kamer
Managing Partner, OurCrowd Qure
Prof. David Sidransky, MD
Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner
Tetsuyuki Maruyama, PhD
Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
Iris Grossman, PhD
Chief Scientific Officer, Camp4 Therapeutics
Prof. Simon Benita, PhD
Head of Nano Delivery Systems, Hebrew University of Jerusalem
Gil Granot-Mayer
CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science
Irit Yaniv, MD
General Partner, Accelmed
Barak Azmon, MD
Ophthalmic Entrepreneur
Yael Weiss, MD, PhD
Vice President Business Development, Ultragenyx
Varda Shalev, MD, MPH
Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services
Michael L. Salgaller, PhD
Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health
Prof. Nir Giladi, MD
Director, Neurology Division, Tel Aviv Sourasky Medical Center
Prof. Gideon Rechavi, MD, PhD
Sheba Cancer Research Center
Prof. Dror Harats, MD
Chief Executive Officer, Vascular Biogenics
Shai Rosenberg, MD
Neuro-Oncology and head of Cancer Computational Biology laboratory, Hadassah – Hebrew University Medical Center
Miro Venturi, PhD
Global Head – Diagnostics Biomarkers, F. Hoffmann-La Roche Ltd.
Randy Prebula
Partner, Hogan Lovells, Washington, D.C.
David Fenstermacher, PhD
Vice President R&D-Bioinformatics, Medimmune
David Cassak
Managing Partner, Innovation In Medtech
Daphna Laifenfeld, PhD
Chief Strategy Officer, Ibex Medical Analytics
Erhan Bilal, PhD
IBM T.J. Watson Research / Computational Biology Center
Anand Subramony, PhD
Vice President, Novel Product Technologies, MedImmune
Tauhid Ali, PhD
Vice President and Head of TAK-celerator, Takeda
Zeev Zehavi
Vice President of Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
Elie Lobel
Chief Executive Officer, Orange Healthcare
Prof. John Gallacher
Director, Dementia Platform UK,
Michael Martin, PhD
Global Head, Takeda Ventures, Inc.
Tal Zaks, MD, PhD
Chief Medical Officer, Moderna Therapeutics
Gil Bar-Nahum, PhD
Managing Director, Jefferies International
Simon Gisby
Managing Director, Deloitte Corporate Finance LLC
Michal Silverberg
Managing Director, Novartis Venture Fund
Prof. Dina Ben-Yehuda, PhD
Dean of the Hadassah-Hebrew University Faculty of Medicine
Prof. Ronit Satchi-Fainaro, PhD
Head, Cancer Angiogenesis and Nanomedicine Laboratory, Sackler Faculty of Medicine, Tel Aviv University
Prof. Jeffrey A. Sosman, MD
Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Marc Funk
COO & President, Lonza Pharma & Biotech
Dan Vesely
Co-founder, CliniCrowd, Partner at Sdemagroup
John D. Halamka, MD, MS
Chief Information Officer, Beth Israel Deaconess System
Joshua Milner, MD
Chief, Laboratory of Allergic Diseases, National Health Institute
Ziv Ofek
Founder and CEO, MDClone
Amir Magner
CEO, CyberMDX
Ofer Tzadik
COO & President, TytoCare
Ariel Beery
CEO, MobileODT
Ran Shaul
Co-Founder and Chief Product Officer, K Health
Prof. Shai Shen-Orr
Chief Scientist, CytoReason; Faculty of Medicine, Technion
Prof. Zohar Yakhini
DNA Storage
Chris Adams, PhD, MBA
Chief Executive Officer, Cydan II Inc.
Prof. Anat Loewenstein MD, MHA
Head, Ophthalmology Division, Tel Aviv Medical Center
Prof. Ehud Assia, MD
Head, Ophthalmology Division, Meir Medical Center
Julia Hawkins
Partner, LocalGlobe
Daniel Fischer
Founder at Tevard Biosciences
Prof. Amir Lerman, MD
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA
Peter H.J. van der Goes, Jr.
Head of Healthcare IT and Digital Health Banking, Goldman Sachs
Prof. Moshe Phillip
Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes
William Shen
Executive Director, Business Development, Bristol-Myers Squibb
Mark Carlton
CSO, Cerevance Therapeutics
Prof. Michael Hornberger
Head of Department of Medicine & Professor of Applied Dementia Research at the Norwich Medical School; Director of Aging Research in the Norfolk & Suffolk Mental Health Trust
Michael C. Irizarry
Vice-President of Early Phase Neurosciences, Eli Lilly
Yuval Mor
CEO, Beyond Verbal
Phil L’Huillier, PhD, MBA
Head, European Innovation Hub, MSD